Listar por autor "Katodritou, E."
Mostrando ítems 1-7 de 7
-
Analysis of SLC40A1(Ferroportin 1) gene at mrna level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV
Speletas, M.; Kioumi, A.; Loules, G.; Kalala, F.; Katodritou, E.; Tsitouridis, I.; Hytiroglou, P.; Christakis, J.; Korantzis, I.; Germenis, A. (2007) -
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients
Katodritou, E.; Terpos, E.; Symeonidis, A. S.; Pouli, A.; Kelaidi, C.; Kyrtsonis, M. C.; Kotsopoulou, M.; Delimpasi, S.; Christoforidou, A.; Giannakoulas, N.; Viniou, N. A.; Stefanoudaki, E.; Hadjiaggelidou, C.; Christoulas, D.; Verrou, E.; Gastari, V.; Papadaki, S.; Polychronidou, G.; Papadopoulou, A.; Giannopoulou, E.; Kastritis, E.; Kouraklis, A.; Konstantinidou, P.; Anagnostopoulos, A.; Zervas, K.; Dimopoulos, M. A. (2014)Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice is local radiotherapy (R/T) +/- surgical excision. The role of ... -
Immunoglobulin D myeloma: Clinical features and outcome in the era of novel agents
Zagouri, F.; Kastritis, E.; Symeonidis, A. S.; Giannakoulas, N.; Katodritou, E.; Delimpasi, S.; Repousis, P.; Terpos, E.; Dimopoulos, M. A. (2014)Objectives: Immunoglobulin D (IgD) multiple myeloma is an uncommon variant of the disease probably associated with poorer prognosis. However, data on IgD myeloma patients treated in the novel agent era are lacking. Methods: ... -
Influence of common thrombophilia polymorphisms on the thrombosis risk in patients with JAK2-V617F-positive myeloproliferative neoplasms
Giamouris, V.; Befani, M.; Papadakis, E.; Mandala, E.; Papadoulis, N.; Karamagiolis, S.; Gastari, V.; Verrou, E.; Katodritou, E.; Lafioniatis, S.; Kartasis, Z.; Magiannis, K.; Marinaki, P.; Tsioni, K.; Kioumi, A.; Germenis, A. E.; Speletas, M. (2012) -
Methylation status of RASSF1A in patients with chronic myeloid leukemia
Avramouli, A.; Tsochas, S.; Mandala, E.; Katodritou, E.; Ioannou, M.; Ritis, K.; Speletas, M. (2009)RASSF1A, a key cell cycle related gene, is expressed in all hematopoietic cells, it is implicated in ras signaling pathway and its promoter hypermethylation is observed in a wide variety of solid tumors. Till now, RASSF1A ... -
TLR4 single nucleotide polymorphisms and thrombosis risk in patients with myeloproliferative disorders
Speletas, M.; Liadaki, K.; Kalala, F.; Daiou, C.; Katodritou, E.; Mandala, E.; Korantzis, I.; Ritis, K.; Zintzaras, E.; Germenis, A. E. (2008) -
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Katodritou, E.; Terpos, E.; Kelaidi, C.; Kotsopoulou, M.; Delimpasi, S.; Kyrtsonis, M. C.; Symeonidis, A.; Giannakoulas, N.; Stefanoudaki, A.; Christoulas, D.; Chatziaggelidou, C.; Gastari, V.; Spyridis, N.; Verrou, E.; Konstantinidou, P.; Zervas, K.; Dimopoulos, M. A. (2014)Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety ...